Developer docs
API playgroundTry for free, no card

Search company profiles

Upfront Diagnostics

Full company profile

uuid00026sq

Namestring
Upfront Diagnostics
Legal namestring
POCKIT Diagnostics Ltd.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Upfront Diagnostics is a Cambridge-based medtech company founded in 2017 that has developed LVOne, marketed as the world's first rapid lateral flow blood test for detecting Large Vessel Occlusion (LVO) strokes at the point of care. LVOne uses a proprietary combination of two biomarkers, D-dimer (clot formation marker) and GFAP (brain bleeding marker), measured via lateral flow immunoassay to deliver a positive/negative LVO classification in under ten minutes from a single finger-prick capillary blood sample. The portable, room-temperature-stable device is intended for use by paramedics and emergency clinicians in ambulances and urgent care settings without the need for additional equipment, addressing the unmet need of identifying thrombectomy-eligible stroke patients prior to hospital arrival where brain imaging is unavailable.

The company's business model is built on enterprise sales of the LVOne device and its consumable test cartridges to ambulance services, hospitals, and stroke networks, deployed through negotiated pilots and partnership contracts rather than publicly listed pricing. UK go-to-market is anchored in pilots with London Ambulance Service (approximately 280 vehicles covering 6.5 million people) and the East of England Ambulance Service NHS Trust, plus clinical evaluations through the RADAR study across six NHS stroke hospitals led by Newcastle University. International expansion is being built through the NordicDx iaX platform partnership, distributor recruitment, and clinical collaborations in the US (TIME study, Harvard Medical School), Puerto Rico (COPILOT), and planned EU entry pending CE marking.

Upfront Diagnostics has secured approximately $7–9 million of combined equity and non-dilutive grant funding across £1.6M seed capital (2023), a $4.3M round led by Phoenix Sustainable Investments with Cambridge Enterprise Ventures (May 2025), and multiple grants from SBRI Healthcare, Innovate UK and CPI. The company achieved UKCA marking and ISO 13485:2016 certification in 2024–2026, is enrolled in the UK IDAP pathway, and remains in pre-revenue or pilot-revenue stage at the time of analysis with headcount of 1–10.

Short descriptiontext

Upfront Diagnostics is a Cambridge, UK medtech company that develops LVOne, the world's first rapid lateral flow blood test for detecting Large Vessel Occlusion strokes in under ten minutes from a finger-prick sample, sold to ambulance services, hospitals and stroke networks globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid stroke diagnostics, point-of-care testing, lateral flow immunoassay, biomarker blood testing, pre-hospital diagnostics
Industry2 codes
PRIMARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Point-of-Care Stroke Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Revenue generated from the sale of LVOne rapid blood test devices and consumables to healthcare providers, ambulance services, and hospital systems. The product is deployed through pilot programs and is expected to generate recurring revenue from consumable test cartridges.

upfrontdiagnostics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise/Healthcare System Pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is negotiated through partnerships and pilot programs with healthcare systems and ambulance services rather than publicly listed.

upfrontdiagnostics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Upfront Diagnostics manufactures and sells LVOne, the world's first rapid lateral flow blood test for detecting Large Vessel Occlusion (LVO) strokes. The handheld point-of-care device uses a proprietary combination of D-dimer and GFAP biomarkers measured from a finger-prick capillary blood sample, delivering results in under 10 minutes without requiring additional equipment. It is designed for pre-hospital use by paramedics and emergency clinicians in ambulances and urgent care settings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 90% accuracy in detecting LVO using GFAP and D-dimer biomarkers
+4 more records
Product overview1 text field

Upfront Diagnostics offers a single core product: LVOne, the world's first rapid lateral flow blood test for stroke diagnosis. LVOne is a handheld point-of-care device that measures two proprietary biomarkers (D-dimer and GFAP) to identify Large Vessel Occlusion strokes within minutes from a finger-prick blood sample. The product is designed for pre-hospital use by paramedics and emergency clinicians, enabling rapid triage decisions and fast-tracking of patients to thrombectomy-capable stroke centres. There is no platform-plus-modules architecture; LVOne is a standalone diagnostic device with no additional product modules or add-ons.

Product and service1 record
1LVOne Rapid Stroke Blood Test
CategoryPoint-of-Care Stroke Diagnostics
Description

LVOne is the world's first rapid lateral flow blood test designed to detect Large Vessel Occlusion (LVO) strokes at the point of care. It uses a proprietary combination of D-dimer and GFAP biomarkers measured from a finger-prick capillary blood sample, delivering results in under 10 minutes without additional equipment. The portable, room-temperature-stable test is intended for use by paramedics and emergency clinicians in ambulances or urgent care settings to accelerate triage of suspected stroke patients to thrombectomy-capable stroke centres.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Six-month pilot deployment of LVOne across approximately 280 vehicles serving North Central, North West, and North East London, covering 6.5 million people. Paramedics test suspected stroke patients using the finger-prick blood test, providing advanced warning to receiving stroke teams.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-30
Description

Multi-institutional partnership to trial the first GFAP lateral flow device for traumatic brain injury detection, extending LVOne technology beyond stroke to TBI applications.

3Hospital Menonita Caguas, Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

COPILOT clinical trial partnership for 24-month evaluation of LVOne performance in Puerto Rico. Hospital is Puerto Rico's premier stroke centre with 24/7 stroke coverage.

upfrontdiagnostics.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-04-04
Description

Strategic partnership to integrate LVOne into NordicDx's iaX portable lateral flow reader platform. This integration enables the first GFAP lateral flow test for stroke on the platform and expands into neurovascular diagnostics.

5Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-19
Description

Collaboration on TIME clinical study validating LVOne accuracy. Harvard neurologists participated in US clinical trial at Brandon Regional Hospital, Florida with 300+ patients.

upfrontdiagnostics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-19
Description

Clinical collaboration for TIME study validating GFAP and D-dimer biomarkers for LVO stroke detection in US emergency settings.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing research partnership with Newcastle University Stroke Research Group led by Professor Chris Price. Conducted RADAR clinical study across multiple NHS hospitals with 500+ patients.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

CDMO partner delivering feasibility through scale-up, quality control, robustness testing, validation, and routine manufacture of LVOne's dual-biomarker assays measuring D-dimer and GFAP.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NHS evaluation of LVOne through RADAR study, SBRI Healthcare support, and inclusion in IDAP pathway for national adoption.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pilot deployment of LVOne in south Cambridgeshire assessing feasibility and safety for routine ambulance use in pre-hospital stroke detection.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-powered stroke triage and workflow coordination platform that identifies suspected LVO strokes and routes patients to thrombectomy-capable centres. Most directly comparable to Upfront on the LVO identification use case for ambulance and emergency-department decision-making, though using imaging AI rather than blood biomarkers.

TypeDirect peer
Description

Stroke imaging AI platform used by hospitals and telestroke networks to detect LVO and accelerate treatment decisions. Competes with LVOne for the same clinical decision point (LVO identification pre- and intra-hospital), with an established installed base across US stroke centres.

TypeDirect peer
Description

POC biomarker-based brain-injury diagnostic (TBI/concussion) using handheld EEG and biomarker approaches. Closely analogous platform model to LVOne — portable, non-imaging, biomarker-driven brain diagnostics — and a natural reference point as Upfront extends LVOne into TBI detection.

TypeDirect peer
Description

Robotic transcranial Doppler platform (NovaGuide) for real-time cerebral blood flow assessment, including pre-hospital and emergency-department LVO detection. Competes with LVOne as an alternative non-imaging modality for rapid LVO identification.

TypeBroad incumbent
Description

Leading mechanical thrombectomy device maker and the downstream beneficiary of accurate LVO triage. Relevant peer because Penumbra's installed base and stroke-centre relationships shape the procurement environment in which LVOne would need to prove clinical-economic value.

TypeBroad incumbent
Description

Large incumbent in neurovascular devices including thrombectomy (Solitaire) and stroke-care workflow. Represents a potential strategic acquirer and a benchmark for what scaled commercial infrastructure in stroke intervention looks like, while its broader portfolio competes for hospital capital budgets.

7Abbott Point of Care
TypeBroad incumbent
Description

i-STAT and related POC blood-analysis platforms used across emergency and ambulance settings. Most relevant broad incumbent for POC diagnostics procurement dynamics, even though Abbott's menu does not currently include an LVO biomarker panel.

TypeBroad incumbent
Description

Major rapid diagnostics and lateral flow immunoassay franchise (e.g., Sofia platform). Comparable as a scaled lateral-flow POC diagnostics operator and a potential strategic/distribution partner for stroke or TBI biomarker assays.

TypeEmerging player
Description

Clinical-stage brain-health diagnostics platform focused on objective CNS measurement in clinic and at home. Relevant emerging peer in the broader brain-diagnostic POC category where LVOne's TBI extension would compete.

TypeOthers
Description

UK-based lateral flow contract development and manufacturing organisation (CDMO) and a current Upfront manufacturing partner. Comparable as a specialist in commercialising lateral flow assays and a natural strategic/distribution counterpart rather than a direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Upfront Diagnostics

Point-of-Care Stroke Diagnosticsupfrontdiagnostics.com

Upfront Diagnostics is a Cambridge, UK medtech company that develops LVOne, the world's first rapid lateral flow blood test for detecting Large Vessel Occlusion strokes in under ten minutes from a finger-prick sample, sold to ambulance services, hospitals and stroke networks globally.

What Upfront Diagnostics does

Upfront Diagnostics is a Cambridge-based medtech company founded in 2017 that has developed LVOne, marketed as the world's first rapid lateral flow blood test for detecting Large Vessel Occlusion (LVO) strokes at the point of care. LVOne uses a proprietary combination of two biomarkers, D-dimer (clot formation marker) and GFAP (brain bleeding marker), measured via lateral flow immunoassay to deliver a positive/negative LVO classification in under ten minutes from a single finger-prick capillary blood sample. The portable, room-temperature-stable device is intended for use by paramedics and emergency clinicians in ambulances and urgent care settings without the need for additional equipment, addressing the unmet need of identifying thrombectomy-eligible stroke patients prior to hospital arrival where brain imaging is unavailable.

The company's business model is built on enterprise sales of the LVOne device and its consumable test cartridges to ambulance services, hospitals, and stroke networks, deployed through negotiated pilots and partnership contracts rather than publicly listed pricing. UK go-to-market is anchored in pilots with London Ambulance Service (approximately 280 vehicles covering 6.5 million people) and the East of England Ambulance Service NHS Trust, plus clinical evaluations through the RADAR study across six NHS stroke hospitals led by Newcastle University. International expansion is being built through the NordicDx iaX platform partnership, distributor recruitment, and clinical collaborations in the US (TIME study, Harvard Medical School), Puerto Rico (COPILOT), and planned EU entry pending CE marking.

Upfront Diagnostics has secured approximately $7–9 million of combined equity and non-dilutive grant funding across £1.6M seed capital (2023), a $4.3M round led by Phoenix Sustainable Investments with Cambridge Enterprise Ventures (May 2025), and multiple grants from SBRI Healthcare, Innovate UK and CPI. The company achieved UKCA marking and ISO 13485:2016 certification in 2024–2026, is enrolled in the UK IDAP pathway, and remains in pre-revenue or pilot-revenue stage at the time of analysis with headcount of 1–10.

Upfront Diagnostics firmographics

Firmographics
Name
Upfront Diagnostics
Legal name
POCKIT Diagnostics Ltd.
Website
https://upfrontdiagnostics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Upfront Diagnostics is a Cambridge, UK medtech company that develops LVOne, the world's first rapid lateral flow blood test for detecting Large Vessel Occlusion strokes in under ten minutes from a finger-prick sample, sold to ambulance services, hospitals and stroke networks globally.
Ownership category
akta.pro rank

Upfront Diagnostics industry classification

Industry
Product category
Point-of-Care Stroke Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAOAH
Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Rapid stroke diagnostics
  • Point-of-care testing
  • Lateral flow immunoassay
  • Biomarker blood testing
  • Pre-hospital diagnostics

Where Upfront Diagnostics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Upfront Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Revenue generated from the sale of LVOne rapid blood test devices and consumables to healthcare providers, ambulance services, and hospital systems. The product is deployed through pilot programs and is expected to generate recurring revenue from consumable test cartridges.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise/Healthcare System Pricing

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Upfront Diagnostics product offering

Product offering

Core offering

Upfront Diagnostics manufactures and sells LVOne, the world's first rapid lateral flow blood test for detecting Large Vessel Occlusion (LVO) strokes. The handheld point-of-care device uses a proprietary combination of D-dimer and GFAP biomarkers measured from a finger-prick capillary blood sample, delivering results in under 10 minutes without requiring additional equipment. It is designed for pre-hospital use by paramedics and emergency clinicians in ambulances and urgent care settings.

Product overview

Upfront Diagnostics offers a single core product: LVOne, the world's first rapid lateral flow blood test for stroke diagnosis. LVOne is a handheld point-of-care device that measures two proprietary biomarkers (D-dimer and GFAP) to identify Large Vessel Occlusion strokes within minutes from a finger-prick blood sample. The product is designed for pre-hospital use by paramedics and emergency clinicians, enabling rapid triage decisions and fast-tracking of patients to thrombectomy-capable stroke centres. There is no platform-plus-modules architecture; LVOne is a standalone diagnostic device with no additional product modules or add-ons.

Differentiator

Problem solved

Functional benefit

Products and services

  • LVOne Rapid Stroke Blood Test LVOne is the world's first rapid lateral flow blood test designed to detect Large Vessel Occlusion (LVO) strokes at the point of care. It uses a proprietary combination of D-dimer and GFAP biomarkers measured from a finger-prick capillary blood sample, delivering results in under 10 minutes without additional equipment. The portable, room-temperature-stable test is intended for use by paramedics and emergency clinicians in ambulances or urgent care settings to accelerate triage of suspected stroke patients to thrombectomy-capable stroke centres.

Quantifiable outcome

  • 90% accuracy in detecting LVO using GFAP and D-dimer biomarkers
  • +4 more outcomes

Companies that use Upfront Diagnostics

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Upfront Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Upfront Diagnostics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and flagship.

  • London Ambulance ServicecoreStrategic or Co-development Partner · 5 May 2026Six-month pilot deployment of LVOne across approximately 280 vehicles serving North Central, North West, and North East London, covering 6.5 million people. Paramedics test suspected stroke patients using the finger-prick blood test, providing advanced warning to receiving stroke teams.
  • Harvard, MIT, Cambridge, and OxfordcoreStrategic or Co-development Partner · 30 July 2025Multi-institutional partnership to trial the first GFAP lateral flow device for traumatic brain injury detection, extending LVOne technology beyond stroke to TBI applications.
  • Hospital Menonita Caguas, Inc.coreStrategic or Co-development Partner · 23 June 2025COPILOT clinical trial partnership for 24-month evaluation of LVOne performance in Puerto Rico. Hospital is Puerto Rico's premier stroke centre with 24/7 stroke coverage.
  • NordicDxflagshipStrategic or Co-development Partner · 4 April 2025Strategic partnership to integrate LVOne into NordicDx's iaX portable lateral flow reader platform. This integration enables the first GFAP lateral flow test for stroke on the platform and expands into neurovascular diagnostics.
  • Harvard Medical SchoolcoreStrategic or Co-development Partner · 19 May 2024Collaboration on TIME clinical study validating LVOne accuracy. Harvard neurologists participated in US clinical trial at Brandon Regional Hospital, Florida with 300+ patients.
  • University of Alabama at BirminghamcoreStrategic or Co-development Partner · 19 May 2024Clinical collaboration for TIME study validating GFAP and D-dimer biomarkers for LVO stroke detection in US emergency settings.
  • Newcastle UniversitycoreStrategic or Co-development PartnerLong-standing research partnership with Newcastle University Stroke Research Group led by Professor Chris Price. Conducted RADAR clinical study across multiple NHS hospitals with 500+ patients.
  • Abingdon HealthcoreImplementation/ SI/ Consulting PartnerCDMO partner delivering feasibility through scale-up, quality control, robustness testing, validation, and routine manufacture of LVOne's dual-biomarker assays measuring D-dimer and GFAP.
  • NHS EnglandcoreStrategic or Co-development PartnerNHS evaluation of LVOne through RADAR study, SBRI Healthcare support, and inclusion in IDAP pathway for national adoption.
  • East of England Ambulance Service NHS Trust (EEAST)coreStrategic or Co-development PartnerPilot deployment of LVOne in south Cambridgeshire assessing feasibility and safety for routine ambulance use in pre-hospital stroke detection.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Upfront Diagnostics competitors and assessment

Company assessment

Direct peers

  • Viz.ai: AI-powered stroke triage and workflow coordination platform that identifies suspected LVO strokes and routes patients to thrombectomy-capable centres. Most directly comparable to Upfront on the LVO identification use case for ambulance and emergency-department decision-making, though using imaging AI rather than blood biomarkers.
  • RapidAI: Stroke imaging AI platform used by hospitals and telestroke networks to detect LVO and accelerate treatment decisions. Competes with LVOne for the same clinical decision point (LVO identification pre- and intra-hospital), with an established installed base across US stroke centres.
  • BrainScope: POC biomarker-based brain-injury diagnostic (TBI/concussion) using handheld EEG and biomarker approaches. Closely analogous platform model to LVOne — portable, non-imaging, biomarker-driven brain diagnostics — and a natural reference point as Upfront extends LVOne into TBI detection.
  • NovaSignal: Robotic transcranial Doppler platform (NovaGuide) for real-time cerebral blood flow assessment, including pre-hospital and emergency-department LVO detection. Competes with LVOne as an alternative non-imaging modality for rapid LVO identification.

Broad incumbents

  • Penumbra: Leading mechanical thrombectomy device maker and the downstream beneficiary of accurate LVO triage. Relevant peer because Penumbra's installed base and stroke-centre relationships shape the procurement environment in which LVOne would need to prove clinical-economic value.
  • Medtronic (Neurovascular): Large incumbent in neurovascular devices including thrombectomy (Solitaire) and stroke-care workflow. Represents a potential strategic acquirer and a benchmark for what scaled commercial infrastructure in stroke intervention looks like, while its broader portfolio competes for hospital capital budgets.
  • Abbott Point of Care: i-STAT and related POC blood-analysis platforms used across emergency and ambulance settings. Most relevant broad incumbent for POC diagnostics procurement dynamics, even though Abbott's menu does not currently include an LVO biomarker panel.
  • QuidelOrtho: Major rapid diagnostics and lateral flow immunoassay franchise (e.g., Sofia platform). Comparable as a scaled lateral-flow POC diagnostics operator and a potential strategic/distribution partner for stroke or TBI biomarker assays.

Emerging players

  • Cumulus Neuroscience: Clinical-stage brain-health diagnostics platform focused on objective CNS measurement in clinic and at home. Relevant emerging peer in the broader brain-diagnostic POC category where LVOne's TBI extension would compete.

Others

  • Abingdon Health: UK-based lateral flow contract development and manufacturing organisation (CDMO) and a current Upfront manufacturing partner. Comparable as a specialist in commercialising lateral flow assays and a natural strategic/distribution counterpart rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Upfront Diagnostics social profiles

Digital presence

Upfront Diagnostics compliance and trust

Trust signal

Compliance2 records

Upfront Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Upfront Diagnostics leadership team

Management profile

Number of profiles

Profiles1 record

Upfront Diagnostics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Upfront Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Upfront Diagnostics

What does Upfront Diagnostics do?

Upfront Diagnostics manufactures and sells LVOne, the world's first rapid lateral flow blood test for detecting Large Vessel Occlusion (LVO) strokes. The handheld point-of-care device uses a proprietary combination of D-dimer and GFAP biomarkers measured from a finger-prick capillary blood sample, delivering results in under 10 minutes without requiring additional equipment. It is designed for pre-hospital use by paramedics and emergency clinicians in ambulances and urgent care settings.

Is Upfront Diagnostics a public or private company?

Upfront Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Upfront Diagnostics founded?

Upfront Diagnostics was founded in 2017. It employs 1 to 10 people.

Where is Upfront Diagnostics based?

Upfront Diagnostics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Upfront Diagnostics make money?

One revenue line is on record: medical Device Sales.

Who are Upfront Diagnostics's main competitors?

Direct peers on record are Viz.ai, RapidAI, BrainScope and NovaSignal. Broad incumbents are Penumbra, Medtronic (Neurovascular), Abbott Point of Care and QuidelOrtho. Cumulus Neuroscience is listed as an emerging player. Abingdon Health is listed as an others.

Does Upfront Diagnostics have an API?

No public API is recorded for Upfront Diagnostics.

What industry is Upfront Diagnostics in?

Upfront Diagnostics's product category is Point-of-Care Stroke Diagnostics. Its primary akta.pro industry code is HLAHAOAH, Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireUpfront Diagnostics and Vingmed Group Partner to Bring Innovative Stroke Diagnostic Technology Across the Nordic RegionUpfront Diagnostics and Vingmed Group announced a partnership to distribute LVOne, a rapid blood test for large vessel occlusion stroke detection, across the Nordic region. Vingmed will serve as the authorised distributor, aiming to decentralise stroke testing and reduce time to thrombectomy. The collaboration is part of Upfront Diagnostics' broader EU distribution strategy.BioSpaceUpFront Diagnostics Announces CE Mark Approval for LVOne — the World’s First Rapid Blood Test to Diagnose StrokeUpFront Diagnostics announced CE mark approval for LVOne, the world's first rapid blood test to diagnose stroke. The approval enables launch across Europe, with UKCA marking and pilot with London Ambulance Service. The company aims to reduce diagnostic times and expand access to emergency teams.EuropeanhhmUpFront Diagnostics Announces CE Mark Approval for LVOne — the World's First Rapid Blood Test to Diagnose StrokeUpFront Diagnostics announced CE mark approval for LVOne, a rapid blood test for stroke diagnosis. The test uses GFAP and D-dimer biomarkers, validated with 500+ patients across six NHS hospitals, and delivers results within 10 minutes. It is UKCA marked and being piloted with the London Ambulance Service.Cambridge IndependentFinalists of the 2026 Cambridge Independent Business Awards revealedThe finalists for the 2026 Cambridge Independent Business Awards were revealed, with winners to be announced on 24 September at a black-tie dinner at King's College. The awards cover 14 categories, including start-ups, retailers, and social enterprises, with sponsors such as Barr Ellison and The Crown Estate.South Wales ArgusWelsh Ambulance Service testing blood test for strokesThe Welsh Ambulance Service is testing the LVOne blood test in a trial with Newcastle University to identify large vessel occlusion stroke. The test checks for two markers, and paramedics transport patients to Swansea's Morriston Hospital. The study could enable faster treatment by diverting patients directly to specialist centres.GlobeNewswireUpfront Diagnostics Announces Global Medical Advisory Board to Accelerate Efforts in Reducing Time to Stroke CareUpfront Diagnostics, a Cambridge-based medtech company developing rapid blood tests for stroke, has appointed a global Medical Advisory Board comprising leading neurologists, stroke physicians, neurosurgeons, and emergency medicine specialists from the United States, United Kingdom, Canada, Spain, Nigeria, and Australia. The advisory board will provide strategic guidance as the company advances next-generation blood biomarkers, including GFAP-based diagnostics, aimed at enabling rapid stroke detection and reducing time to treatment. The company is pursuing commercial evaluations and clinical partnerships across multiple countries in 2026, with its flagship product LVOne already UKCA marked and currently being piloted in partnership with the London Ambulance Service.YahooUpfront Diagnostics Announces Global Medical Advisory Board to Accelerate Efforts in Reducing Time to Stroke CareUpfront Diagnostics appointed a global medical advisory board of stroke experts from six countries to guide its rapid blood tests for stroke. The board will support development of GFAP-based diagnostics to reduce time to treatment. The company plans additional commercial evaluations and clinical partnerships in 2026.BriefglanceUpfront's Global Gambit: A Strategic Play to Beat the Clock on StrokeUpfront Diagnostics formed a global medical advisory board to accelerate its LVOne stroke test, which identifies large vessel occlusion with 90% accuracy and 93% specificity. The company raised $4.3 million for US regulatory approval and global commercialization, with a London pilot testing the test in 280 ambulances.UpfrontdiagnosticsHow a Simple Finger-Prick Test Transformed My Mum’s Stroke Journey and Helped to Save Her LifeA family's mother suffered a stroke, and paramedics used a finger-prick blood test to identify a large vessel occlusion, enabling direct transfer to a specialist hospital. The test bypassed delays, and she is now recovering with speech therapy. Rapid diagnostics like LVOne are transforming stroke response.PathologyinpracticeUK launch for LVOne stroke testUpfront Diagnostics launched LVOne, a rapid blood test for large vessel occlusion strokes, with UKCA marking and deployment in London Ambulance Service. The pilot will equip 280 vehicles covering 6.5 million people, delivering results in under 10 minutes. The company expects broader adoption beyond the initial London programme.